This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
A patient prepares to undergo a MRI at the Oscar Lambret Center in Lille, northern France, a regional medical unit specialised in cancer's treatment, on Feb. 6, 2013. Philippe Huguen/AFP/Getty Images
$2.4 million. $1.5 million. $2.28 million. These are the amounts of money the health system where I work, teach, and receive health care spent purchasing a PET scanner, a CT scanner, and a three-month supply of pembrolizumab, a drug that treats a variety of solid-organ cancers.
Michael Williams is an associate chief medical officer for Clinical Integration; associate professor of Surgery and director of the UVA Center for Health Policy at the University of Virginia.
